Expanding opportunities for mining bioactive chemistry from patents  by Southan, Christopher
TECHNOLOGIES
DRUG DISCOVERY
TODAY
Expanding opportunities for mining
bioactive chemistry from patents
Christopher Southan
IUPHAR/BPS Database and Guide to PHARMACOLOGY Web Portal Group, Centre for Integrative Physiology, School of Biomedical
Sciences, University of Edinburgh, Hugh Robson Building, Edinburgh EH8 9XD, UK1
Drug Discovery Today: Technologies Vol. 14, 2015
Editors-in-Chief
Kelvin Lam – Simplex Pharma Advisors, Inc., Boston, MA, USA
Henk Timmerman – Vrije Universiteit, The Netherlands
From Chemistry to Biology Database CurationBioactive structures published in medicinal chemistry
patents typically exceed those in papers by at least
twofold and may precede them by several years. The
Big-Bang of open automated extraction since 2012 has
contributed to over 15 million patent-derived com-
pounds in PubChem. While mapping between chemi-
cal structures, assay results and protein targets from
patent documents is challenging, these relationships
can be harvested using open tools and are beginning to
be curated into databases.
Introduction
Compared to papers, patents in the biological sciences have
hitherto been an underexploited information source, princi-
pally because retrieval specificity and data extraction is more
challenging [1]. However, the World Intellectual Property
Organisation (WIPO) indexing of 2.4 million PCT (WO) pub-
lications indicates 8.4% are assigned the International Patent
Classification (IPC code) A61K (medical, veterinary science
and hygiene) that encompasses bioscience filings [2]. Medici-
nal chemistry as C07D (heterocyclic compounds) represents
3.1%. This article focuses on the 1.5% subset of C07D (and)
A61K filings for two main reasons. Firstly, the data mining
challenges for bioscience patents as a whole are too diverse
(including millions of sequence listings) to be covered here [3].
Secondly, for medicinal chemistry, patents have a central
importance, because they not only underpin over four decades
of drug discovery research (both commercial and academic)E-mail address: (cdsouthan@hotmail.com)
1 http://www.guidetopharmacology.org/
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but also contain substantially more structure–activity relation-
ship (SAR) results than journals. This article will focus on
exploring scientific value rather than intellectual property
(IP) because, while both aspects are intertwined, the analytical
approaches diverge. A short video accompanies this article.
Value
The question needs to be posed as to what data-centric patent
mining has to offer practitioners in cheminformatics, phar-
macology, medicinal chemistry or chemical biology. To an-
swer this, it is necessary to compare the availability of data
from non-patent sources. The appearance of ChEMBL in 2009
substantially increased the scale of results accessible from
medicinal chemistry journals, with the current (release 19)
count of 1.41 million structures including 0.94 million
extracted from 57K papers (n.b. because ChEMBL subsume
CIDs from confirmed PubChem BioAssays their compound
count in situ exceeds the ChEMBL source count inside Pub-
Chem) [4]. However, specialised databases have been curating
SAR data from the literature for some years prior to this,
including BindingDB [5], Guide to PHARMACOLOGY
(GtoPdb, formerly IUPHARdb) [6], GLIDA [7] and PDSP [8].
In addition, there are 0.41 million compounds flagged as
‘active’ in PubChem Bioassay (http://www.ncbi.nlm.nih.
gov/pcassay) from sources other than ChEMBL.
The utility of engaging with patents as an adjunct to non-
patent sources can be introduced via a practical example. The
WIPO database provides a searchable interface for patentsi.org/10.1016/j.ddtec.2014.12.001 3
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for BACE* AND inhibitor(s), front page, English PCT applica-
tions) gives 280 results. The first two documents, both pub-
lished on May 1st 2014, were WO2014066132 from Eli Lilley
[9] and WO2014065434 from Shionogi [10], both specifying
BACE1 inhibitors for Alzheimer’s disease (6132 used BACE as
a synonym for BACE1, UniProt P56817). These are shown in
Fig. 1, together with the extraction of two example structures
linked to activity data.
Connections gained from this result included the follow-
ing:
1. Using the same search parameters, it was established that
Shionogi had published nine BACE1 patents since 2007Figure 1. Finding and extracting selected examples from WO2014066132 an
highlighted in green. In the lower-left panel, example 72 from 5434 (page 238 in t
(page 249). The structure was determined from an initial image conversion using
which PubChem searches were launched. The SMILES and InChIKey are show
FC4 C([C@@]1(N C(OC2C1COC2)N)C#C)C C(NC( O)C3 CN C(O
InChIKey = SOYARSISURDFSW-SKMDKRRUSA-N.
In the lower-right panel example 8 from 6132 is shown (page 60 in the PDF) that h
IUPAC name was used to generate a range of molecular outputs including a S
CC(C)(O)C1 C(F)C NC( N1)N1C[C@H]2CSC(N) NC2(C1)C1 CN C
InChIKey = IKIJFJKFIYFTBZ-YOZOHBORSA-N.
4 www.drugdiscoverytoday.comand Eli Lilley five since 2005 (all potentially extractable as
described in this section).
2. The rendering of images and tables in-line with text
(except the Shionogi PDF exceeded the page limit)
allowed scanning of results but full PDFs could be down-
loaded for checking.
3. The structure and associated IC50 values for selected
potent BACE1 inhibitors, were discerned using chemica-
lize.org for the former and the result tables for the latter.
4. As ascertained by a PubChem search, example 8 from
6132 was identified in CID 73603937, deposited as the
HCL by Thomson Pharma on 12th of May (presumably
extracted from the same patent) but no close analogues
were found.Drug Discovery Today: Technologies
d WO2014065434. In the upper panel the search term matches are
he PDF) was reported to have an IC50 against purified enzyme of 13.6 nM
 OSRA [11] and subsequently edited in the PubChem sketcher [12] from
n below.
CF)C N3)C C4
as a reported IC50 of 105 nM (on page 63). Using chemicalize.org [13], the
MILES string and the InChIKey below.
C N1
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Box 1. Utility and challenges of patent data
Utility
 Relationships between the entities of document, assay description,
assay result, compound structure and protein identifier (D-A-R-C-
P) can be identified.
 Other target types (e.g. tumour cells, bacteria or protozoal
parasites) may also have activity results.
 SAR tables (e.g. Ki or IC50) can include hundreds of novel
structures.
 Only a proportion may appear in papers (roughly 10–30%) years
later, or never.
 Many inventor teams include highly cited medicinal chemistry
authors.
 Exemplified compounds are usually supported by synthesis
descriptions and analytical data.
 The combination of references, plus the examiner’s report, provides
a citation network of papers and patents.
 The non-redundant medicinal chemistry corpus (as WO
documents) is freely available for metadata querying and text mining
from many open sources.
 Recent US patent XML includes electronic structures as Complex
Work Units (CWUs), improved text quality and consequent better
CNER extraction.
 Additional bioactivity data may be included (e.g. cell lines, rodent
models, target specificity cross-screening, P450 profiling or other
ADMET results).
 Patents may have complementary data content to journal
publications, for example where chemotype similarity connections
can be made via ChEMBL.
 Biological domain coverage can be widened (e.g. additional PCT
codes for antinfectives, tropical diseases, pesticides and
agrochemicals).
 The majority of exemplified patent chemistry is not only already in
PubChem but also via the InChIKey, can be structure-matched by a
Google search in about 0.2 s [21].
Challenges
 Some patents exemplify most, or even all, analogues without explicit
activity results.
 Binned activity values are less useful than discrete ones for SAR
modelling.
 Various forms of deliberate obfuscation are common, including
uninformative titles, confusing or missing data relationships, virtual
enumerations and prophetic protocols (i.e. not actually executed).
 Judging the scientific and technical quality of patent-only results is
difficult.
 Complexity of large document sets related by patent family and kind
codes, publishing identical content years apart.
 In terms of drug discovery, only a small proportion of C07D
documents have SAR value, because a lead compound series first-
filing is followed by many secondary patents from originators,
competitors or generics companies.
 Open CNER resources extract all chemistry, regardless of IPC code.
Thus, a proportion of structures (i.e. from patents not in C07D and
A61K) have neither linked bioactivity nor biological relevance.
 Whereas patents quote relevant papers (as mandated for US
applications), the citing of patents by journal authors is patchy.
 Even basic data content statistics are essentially unknown (e.g. the %
documents using full IUPAC names vs images, or both, for
exemplifications).
 Automatic extraction says nothing about associated IP claims. Ipso
facto not all patent-extracted structures are ‘patented’ (but they are
prior-art by definition).5. While example 75 from 5434 had no exact match (i.e.
was novel at that time) 60 analogues were found in
PubChem by searching at 90% similarity. Many of these
(e.g. CID 68164415) connected, via SureChEMBL, to a
Roche BACE1/BACE2 filing, US20120202803 [14] and
one (CID 71619629 via ChEMBL) connected between a
Roche paper [15] and a Protein Data Bank experimental
3D ligand structure (4J0P).
6. In 6132, example 8 had cell line and mouse in vivo data
(indicating this to be a possible lead compound).
7. 5434 describes 123 analogues with 15 specified sub-
200 nM IC50s.
8. 6132 describes 114 analogues with three specified IC50s.
9. Detailed chemical synthesis, analytical data and assay
descriptions in both documents.
10. 5434 cites 44 related patents and 3 papers, while 6132
cites one of each.
11. While chemicalize.org was able to automatically extract
structures from the full text at Free Patents Online,
example structures could only be extracted via their
IUPAC name strings from 6132 (because structures in
5434 were image-only).
12. While medicinal chemistry papers from both companies
have been extracted into ChEMBL (66 from Shionogi and
265 from Eli Lilly, including some on BACE1 inhibition)
it could be at least 18 months before compounds from
these patents appear in a journal article and sometime
after that before a ChEMBL release surfaces the published
structures in PubChem.
13. Since this search was carried out, both documents have
been processed in SureChEMBL (n.b. this source is cur-
rently still designated SureChem for the pre-2013 entries
in PubChem).
Aspects related to the search example are expanded as
general points in Box 1. In addition, some of the themes
are addressed in the following sections.
Speed
For operations filing patents that include novel compounds
with commercially useful bioactivity, rapid interrogation of
patent chemistry is an imperative. Because they are also likely
to licence commercial databases for prior-art checking and
competitive intelligence, the timing at which patent struc-
tures surface ‘in the wild’ is less of an issue (except to note that
public sources must now be included in prior-art searches).
Nevertheless, the scientific preview opportunities offered by
medicinal chemistry patents can also be valuable for those
not necessarily committed to filing themselves (Box 1). In this
respect, it may not be appreciated how level the information
playing field is become, because a patent becomes open and
globally accessible only on the day of publication. This means
that, as shown in Fig. 1, using relatively straightforward openwww.drugdiscoverytoday.com 5
Drug Discovery Today: Technologies | From Chemistry to Biology Database Curation Vol. 14, 2015
Table 1. Comparative assessment of patent structures inside PubChem. The specified sources can be retrieved from PubChem
by simple selects (e.g. ‘SureChem’[SourceName] but note this is now SureChEMBL) with the results as CID counts. PubChem
and ChEMBL are included for comparison. Totals are in millions for each source and dates are from the last update. Subsequent
columns are filters expressed as %. In order these are; stereo and E/Z (completely or partially unspecified), Mw < 400, unique
structures (to that source), entries with two components, rule-of-five with 200-800 Mw range. Int. refers to links to patent
documents provided inside PubChem. Ext. refers to document mappings in the source links
Source Total Date Stereo & E/Z Mw < 400 Unique Mix. ROF 2-800 Int. link Ext. link
PubChem 49.8 May-14 35% 58% 52% 2.5% 72%
IBM 2.3 Jun-12 41% 71% 31% 0.3% 58% Yes Yes
SureChem 9.3 Mar-13 38% 52% 52% 5.9% 63% No Yes
SCRIPDB 3.9 Aug-12 29% 48% 27% 5.4% 56% Yes Yes
ChEMBL 0.9 Apr-14 26% 48% 17% 1.9% 61%
Thomson Pharma 4.2 May-14 25% 49% 15% 4.0% 53% No Noa
Total from pats. 15.5 May-14 35% 52% 47% 4.7% 57%
a Signifies the out-links are subscriber-only.resources and tools, key SAR can be extracted from the
document within hours. In addition to day-one publication
at the major offices, the lag-time for new patents to appear in
open searchable sources such as Google Patents (http://www.
google.com/advanced_patent_search), Free Patents Online
(http://www.freepatentsonline.com/), Patent Lens (http://
www.lens.org/lens/) and others, is now reduced to days.
However (as specified in Table 1) current PubChem sources
(except Thomson Pharma) have a submission lag for patent
chemistry. However the recently enhanced SureChEMBL
pipeline in situ (i.e. not yet in PubChem) now has a chemistry
extraction time of less than a week. A practical preview
example can be given for the case of BACE2 as a new diabetes
target [16]. Only one targeted inhibitor has appeared in
a 2011 paper but, since 2010, many hundreds have been
exemplified as different chemotypes in patents published
from four pharmaceutical companies and one academic in-
stitution. In addition, most of these included discrete activity
data and comparative BACE1 cross-screening results. Thus, in
the five years since the first published patents, no papers
describing extensive chemistry directed against this impor-
tant new therapeutic target have yet appeared.
Scale and quality
‘So how do we know more bioactive chemistry is available
from patents than papers?’ There are different data sets to
approach this question but each has caveats. An upper limit is
provided by the GVKBIO Online Structure Activity Relation-
ship database (GOSTAR https://gostardb.com/gostar/). As a
manually curated SAR-focused suite of databases for pub-
lished and patented inhibitors against biological targets over
the past 40 years, it currently includes 6.3 million chemical
structures. A caveat is that a proportion of the patent activity
measurements are binned rather than discrete values. A
recent analysis of a 20-year slice of this data set provided6 www.drugdiscoverytoday.comsome relevant statistics [17]. Firstly a total document ratio for
patents: papers of 58:82 (thousand), secondly a compound
ratio of 2.7:1 (million) and thirdly, an individual extracted
structures per-document ratio of 12:46.
Additional data slices related to the patents: papers ratio
can be made inside PubChem. The sum of all large patent-
extracted sources (Table 1) is 15.4 million. The equivalent
total for literature-linked compounds (via ChEMBL and
PubMed/MeSH) is just over 1.0 million. The intersect (struc-
tures common to both) is 0.5 million. While this indicates
an approximate patents: papers structure ratio of 15:1 there
are caveats to what this represents in bioactivity terms,
especially because none of the larger patent sources in Pub-
Chem currently connect structures directly to data. The intra-
PubChem numbers are informative but it is necessary to
ascertain selectivity to understand source complementarity
[18]. Aspects of this are detailed in Table 1, along with metrics
related to quality.
The dates indicate that IBM, SureChem and SCRIPDB are
currently frozen. Additional date cutting indicates that
ChEMBL releases are approximately tri-annual but Thomson
(Reuters) Pharma submits every week. The stereo and E/Z
filters are quality indicators (e.g. the highly curated source,
ChEBI, scores 16%). The other manual extractions (ChEMBL
and Thomson Pharma) score higher than the automated
chemical named entity recognition (CNER) pipelines but,
of the latter, SCRIPDB does better than IBM. Slicing the Mw
distribution at 400 is a rough proxy for the length of name
strings converted in CNER. Here again, as expected, manual
extraction sources score higher (because they select com-
plete structures in the first place). Causes for the low IBM
score include R-group inclusions and the splitting of longer
IUPAC names. Pragmatically, compared to the major bene-
fits of being able to access them at all, the quality of open
patent-extracted structures is of lesser importance (it may be
Vol. 14, 2015 Drug Discovery Today: Technologies | From Chemistry to Biology Database Curationfor prior-art searching but this is a different issue). Reasons
for this include: (a) the value lies primarily in the
document > assay > result > compound > protein (D-A-R-
C-P) relationships, so even if C (compound) has only a
similarity match (e.g. due to an error in another C), the
relevance of the connection can usually be resolved; (b)
mistakes, isomeric variation and other forms of representa-
tional ‘noise’ in the original documents largely determineFigure 2. Examples of curated and annotated database mappings from patents. T
entry (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligan
P08246) inhibitor. The curator’s notes and the two references are shown; inclu
connectivity for this entry has been added for the next update). The lower panel s
US8541427 [20] on BACE1 inhibitors.extraction quality per se; (c) different extracted isomers and
tautomers can be connected (i.e. via the C-to-C match) or
same connectivity relationships inside PubChem; (d) both
objective quality measurements and structures-in-common
between independent sources are important to assess for any
large sets of structures (i.e. not just from patents) and (e)
reassuring levels of extraction concordance are not only
formally recorded within PubChem via substances (SIDs)Drug Discovery Today: Technologies
he upper panel shows part of the Guide to PHARMACOLOGY (GToPdb)
dId=6476) for AZD9668 as a clinically tested neutrophil elastase (UniProt
ding a SureChEMBL link to the patent US20070203129 [19] (additional
hows one of the views on BindingDB for PubChem CID 44247663 from a
www.drugdiscoverytoday.com 7
Drug Discovery Today: Technologies | From Chemistry to Biology Database Curation Vol. 14, 2015from different patent sources, but also, in SureChEMBL, this
extends to multiple intra-document and inter-document
structure identities within the same patent family.
Uniqueness, indicated by structures in only one source, is a
useful value indicator but not without caveats. The figures
(Table 1) suggest that the SureChem CNER extraction has
contributed the most novel patent structures, However, a
proportion of these could be alternative representations of
the same canonical forms in other sources (although this
measurement is confounded for comparisons between
ChEMBL and Thomson Pharma, because they share some
of the same journal sources). The two-component count
identifies 5% mixtures in SCRIPDB and SureChem (mostly
salts) but IBM appear to have filtered these out. The next
category is a crude lead-like molecular property filter. The
sources converge at around 50–60% for patent structures.
Thus, even if these do not have explicit assay results, they
represent a large and generally synthetically accessible, po-
tential bioactive chemical space. The last two columns in
Table 1 refer to structure-to-document connectivity. Inside
the CID records those with links to the USPTO website are
processed from IBM and SCRIPDB by PubChem. They are also
usefully IPC-indexed by which we can establish that of the 8.5
million structures assigned codes, 7.2 million are under C07
and 6.1 million C07D. Note that the SureChem records
match SureChEMBL externally where a structure search con-
nects to them to patent numbers (also IPC indexed) from the
major offices. For Thomson Pharma, the 4.2 million exter-
nal links are subscription-only but can be either to a patent
and/or a paper (it would seem probable that the chemistry
curation split is similar to GOSTAR that is 3:1 patents:
papers).
Relationship annotation in databases
The BACE1 examples above (Fig. 1) show that D-A-R-C-P
mapping from an individual document requires curation.
Any scaled-up availability of this (analogous to that done
for papers in ChEMBL) has hitherto been a feature of a limited
number of commercial databases. Nevertheless, example
entries from new initiatives in two open databases are shown
(Fig. 2).
In GtoPdb the paper and the patent were connected by
curatorially establishing identical structures for CID
46861623 and the IPUAC name. The journal publication
focuses on the pharmacology of AZD9668 (i.e. this is not
an SAR paper and may therefore neither be picked up by
ChEMBL nor consequently PubChem BioAssay). The com-
plementarity of the curated pointer to the patent for anyone
interested in this drug is both an extensive set of analogues
and unpublished data. Note that AZD9668, as patent example
94, has Kd results converted to Ki but an IC50 only in the
paper. However, seven analogues have IC50 data in the
patent, including the most potent (example 32 at 3 nM) as8 www.drugdiscoverytoday.comCID 11478818 (n.b. the patent may have been filed before
AZD9668 was selected for development). While a limited
number of GtoPdb entries have patent connections so far,
more are being added, particularly for those clinical candi-
dates with little or no SAR in papers.
The patent curation in BindingDB, initiated in Sept 2013, is
also of high utility but takes a different approach. In this case,
the selection of recent US patents is protein target-based. The
BACE1 filing in Fig. 2 has 42 example structures (via CWUs)
manually aligned with their activity data from the patent
tables but intersected with PubChem CIDs, BindingDB SIDs
and a short assay description. For example, the record (http://
www.bindingdb.org/data/mols/tenK10/MolStructure_
102939.html), was extracted from US8541427 [20]. While
this does not locate the structure within the document (i.e.
searching SureChEMBL, via CID 44247663, connects to the
image for example 10), it does allow the curated set to be
directly retrieved as a CID list with the PubChem query
‘US8541427’. This can be done for any of the 367 BindingDB
patents (Oct 2014) covering 32 670 compounds with target-
mapped activity results.
Conclusions
The options to mine patent data from individual documents
up to large extracted structure sets are expanding in open
resources. For example, SureChEMBL has reached 15.6 million
in situ at 80 K novel structures per month (Dr. G. Papadatos,
RDKit UGM, presentation Nov 2014). Paradoxically, patents
are fully accessible for text-mining, in contrast to most of
the literature. Of the patent-extracted structures already in
PubChem over 9 million are within the property boundaries
for potential bioactivity and 0.5 million intersect with
identical structures from papers, via ChEMBL and/or
PubMed. Future challenges will include abstracting D-A-R-
C-P relationships and synergistically intersecting these
with the analogous relationships and entities identified from
the literature, as already demonstrated by BindingDB and
GtoPdb.
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